These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 23594434)

  • 1. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
    Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
    Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
    Kast RE; Karpel-Massler G; Halatsch ME
    Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
    Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
    Kast RE; Ramiro S; Lladó S; Toro S; Coveñas R; Muñoz M
    J Neurooncol; 2016 Feb; 126(3):425-31. PubMed ID: 26603162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma.
    Chantzi E; Hammerling U; Gustafsson MG
    Comput Biol Med; 2024 Aug; 178():108748. PubMed ID: 38925084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
    Halatsch ME; Kast RE; Karpel-Massler G; Mayer B; Zolk O; Schmitz B; Scheuerle A; Maier L; Bullinger L; Mayer-Steinacker R; Schmidt C; Zeiler K; Elshaer Z; Panther P; Schmelzle B; Hallmen A; Dwucet A; Siegelin MD; Westhoff MA; Beckers K; Bouche G; Heiland T
    Neurooncol Adv; 2021; 3(1):vdab075. PubMed ID: 34377985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
    J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
    Kilickap S; Oztoprak I; Yucel B
    Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
    Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
    J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
    Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
    Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
    Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
    Kast RE; Halatsch ME
    Arch Med Res; 2012 Apr; 43(3):243-7. PubMed ID: 22564423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
    Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
    Huang J; Campian JL; Gujar AD; Tsien C; Ansstas G; Tran DD; DeWees TA; Lockhart AC; Kim AH
    J Neurooncol; 2018 May; 138(1):105-111. PubMed ID: 29374809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.